Back to Search
Start Over
Antisense Oligonucleotide: Basic Concepts and Therapeutic Application in Inflammatory Bowel Disease
- Source :
- Frontiers in Pharmacology, Vol 10 (2019), Frontiers in Pharmacology
- Publication Year :
- 2019
- Publisher :
- Frontiers Media S.A., 2019.
-
Abstract
- Several molecular technologies aimed at regulating gene expression that have been recently developed as a strategy to combat inflammatory and neoplastic diseases. Among these, antisense technology is a specific, rapid, and potentially high-throughput approach for inhibiting gene expression through recognition of cellular RNAs. Advances in the understanding of the molecular mechanisms that drive tissue damage in different inflammatory diseases, including Crohn's disease (CD) and ulcerative colitis (UC), the two major inflammatory bowel diseases (IBDs) in humans, have facilitated the identification of novel druggable targets and offered interesting therapeutic perspectives for the treatment of patients. This short review provides a comprehensive understanding of the basic concepts underlying the mechanism of action of the oligonucleotide therapeutics, and summarizes the available pre-clinical and clinical data for oligonucleotide-based therapy in IBD.
- Subjects :
- 0301 basic medicine
Crohn’s disease
antisense oligonucleotide
Mini Review
Druggability
Disease
Bioinformatics
Inflammatory bowel disease
03 medical and health sciences
0302 clinical medicine
RNA interference
inflammatory bowel disease
Antisense Technology
medicine
Pharmacology (medical)
ulcerative colitis
Pharmacology
Crohn's disease
business.industry
Oligonucleotide
lcsh:RM1-950
medicine.disease
Ulcerative colitis
030104 developmental biology
lcsh:Therapeutics. Pharmacology
030220 oncology & carcinogenesis
business
Subjects
Details
- Language :
- English
- ISSN :
- 16639812
- Volume :
- 10
- Database :
- OpenAIRE
- Journal :
- Frontiers in Pharmacology
- Accession number :
- edsair.doi.dedup.....a3dd6f3fb25d7ce36edb7f78973cd064
- Full Text :
- https://doi.org/10.3389/fphar.2019.00305/full